Articles: nausea.
-
Randomized Controlled Trial Multicenter Study Clinical Trial
Intravenous dolasetron mesilate ameliorates postoperative nausea and vomiting.
To compare the efficacy, safety, and tolerability of dolasetron mesilate with placebo for the treatment of postoperative nausea and vomiting (PONV). ⋯ Single doses of dolasetron mesilate iv, given after the first episode of PONV, were both effective and safe in this adult patient population.
-
Anesthesia and analgesia · Feb 1997
Randomized Controlled Trial Comparative Study Clinical TrialAcupressure versus intravenous metoclopramide to prevent nausea and vomiting during spinal anesthesia for cesarean section.
Nausea and vomiting occur frequently during cesarean section under spinal anesthesia. Metoclopramide reduces intraoperative nausea and vomiting, but not without potential side effects. Acupressure, a noninvasive variation of acupuncture that involves constant pressure on the wrist, has been suggested as an alternative method to prevent nausea and vomiting. ⋯ Group I patients received acupressure bands + 2 mLIV saline, Group II patients received placebo wrist bands + 10 mg IV metoclopramide, and Group III patients received placebo wrist bands + 2 mL IV saline. Patients who received either acupressure or metoclopramide prior to initiation of spinal anesthesia for cesarean section had much less nausea than patients in the placebo group. Acupressure is an effective, non-pharmacologic method to reduce intraoperative nausea during elective cesarean section in the awake patient.
-
Randomized Controlled Trial Multicenter Study Clinical Trial
Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian Group for Antiemetic Research.
The role of 5-HT3 receptor antagonists in the prevention of chemotherapy-induced delayed emesis is controversial. We compared ondansetron and metoclopramide, both combined with dexamethasone, in cisplatin-treated patients. ⋯ The two treatments offer similar protection from delayed emesis, although ondansetron plus dexamethasone may be preferred in patients who suffer from acute vomiting. Optimal control of acute emesis is essential to achieve good protection from delayed nausea and vomiting, irrespective of the antiemetic treatment received.
-
Support Care Cancer · Jan 1997
Randomized Controlled Trial Multicenter Study Comparative Study Clinical TrialA double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy.
The potent serotonin receptor (5-HT3) antagonists are new highly selective agents for the prevention and control of chemotherapy-induced nausea and vomiting that have been shown to be comparable to or more effective than traditional metoclopramide regimens. This study was designed to compare the antiemetic efficacy of dolasetron and metoclopramide in chemotherapy-naive and non-naive cancer patients receiving high-dose cisplatin-containing chemotherapy. This multicentre, double-blind, randomized trial compared the efficacy and safety of single i.v. doses of dolasetron mesilate salt (1.2 or 1.8 mg/kg) and metoclopramide (7 mg/kg) in 226 patients for the prevention of acute emesis and nausea associated with the administration of high-dose (> or = 80 mg/m2) cisplatin. ⋯ In conclusion, dolasetron mesilate was effective for the prevention of CINV with high-dose cisplatin. Single i.v. doses of dolasetron mesilate were more effective than 7 mg/kg metoclopramide in preventing nausea and vomiting induced by highly emetogenic cisplatin-containing chemotherapy. In addition, 1.8 mg/kg dolasetron mesilate consistently produced the highest response rates and appears to be the most effective dose for further clinical development.
-
Acta Anaesthesiol Belg · Jan 1997
Randomized Controlled Trial Multicenter Study Clinical TrialSingle i.v. bolus dose of ondansetron in the prevention of postoperative nausea and emesis.
In this placebo controlled, double blind multicentre study, the efficacy and safety of a single i.v. bolus dose of ondansetron 4 mg were evaluated in the prevention of postoperative nausea and vomiting (PONV), which remains one of the most unpleasant side effects experienced by patients postoperatively. The study population included patients having general anesthesia and undergoing major gynecological or elective abdominal surgery by laparoscopy. ⋯ Several factors appeared to be associated with an increased risk of developing PONV, namely gender (female), type of surgery (gynecological), experience of previous PONV and duration of anesthesia; the use of propofol was not a significant factor. Ondansetron was well tolerated, with no side effect being reported as a significant problem.